Axsome (AXSM) Q2 Revenue Soars 72%

Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, released its earnings on August 4, 2025. The company reported GAAP revenue of $150.0 million, up 72% compared to the prior year period, and a net loss per share of $(0.97) (GAAP), which beat consensus GAAP revenue estimates (estimated at $138.25 million) and EPS (GAAP, estimated at $(1.05)). Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the company remains unprofitable, posting a GAAP net loss of $48.0 million. Overall, the quarter featured strong top-line momentum and notable execution on its commercial and research initiatives. Source: Analyst estimates for the quarter provided by FactSet. Axsome Therapeutics is dedicated to developing and commercializing medicines for conditions affecting the brain and nervous system. Its primary focus is on diseases with limited existing treatment options, such as depression, sleep disorders, migraine, narcolepsy, and other CNS-related conditions. The firm differentiates itself by using novel or repurposed compounds to address these unmet medical needs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool